Status | Study |
Recruiting |
Study Name: NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery Condition: Gliosarcoma Recurrent Glioblastoma Date: 2017-01-11 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: BPM31510 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Previously Treated With Bevacizumab Condition: Gliosarcoma Recurrent Glioblastoma Date: 2017-01-05 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients Condition: Glioblastoma Gliosarcoma Date: 2016-01-14 Interventions: Drug: Temozolomide |
Withdrawn |
Study Name: Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma Condition: Glioblastoma Gliosarcoma Date: 2015-11-04 Interventions: Drug: Temozolomide |
Enrolling by invitation |
Study Name: Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 Condition: Glioblastoma Date: 2015-04-23 Interventions: Drug: MK - 3475 Administered I |
Recruiting |
Study Name: Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Condition: Gliosarcoma Supratentorial Glioblastoma Date: 2014-12-08 Interventions: Biological: Ipilimumab Given I |
Active, not recruiting |
Study Name: DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors Condition: Glioblastoma or Gliosarcoma Date: 2014-07-20 Interventions: Drug: Single intratumoral injection of DNX-2401 |
Recruiting |
Study Name: Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme Condition: Histologically Proven Diagnosis of Glioblastoma or Gliosarcoma (WHO Grade IV) Date: 2013-03-22 Interventions: Drug: Chemotherapy with Temodar. |
Active, not recruiting |
Study Name: Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma Condition: Giant Cell Glioblastoma Glioblastoma Date: 2010-06-22 Interventions: Biological: bevacizumab Given |
Completed |
Study Name: Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Condition: Glioblastoma Multiforme GBM Gliosarc Date: 2010-05-12 Interventions: Drug: AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) IV AR-67 administered once daily for 5 day |